Nusinersen (SpinrazaTM): The First FDA Approved Treatment for SMA

Nusinersen: The First Approval for Spinal Muscular AtrophyПодробнее

U.S. FDA Approves Biogen’s SPINRAZA™ (nusinersen), The First Treatment for Spinal Muscular AtrophyПодробнее

U.S. FDA Approves Biogen’s SPINRAZA™ (nusinersen), The First Treatment for Spinal Muscular AtrophyПодробнее

Nusinersen for Treatment of SMAПодробнее

Spinraza (nusinersen) ApprovalПодробнее

The Development Journey of Spinraza® (nusinersen): From Advocacy to Treatment and BeyondПодробнее

Approval of Nusinersen for SMAПодробнее

SPINRAZA® (nusinersen) Mechanism of Action in Spinal Muscular AtrophyПодробнее

Cut and Paste: Treating Spinal Muscular Atrophy with NusinersenПодробнее

How Spinraza (nusinersen) and Evrysdi treat Spinal Muscular Atrophy (SMA) through splice-switchingПодробнее

Nusinersen Treatment for SMAПодробнее

Spinal Muscular Atrophy 2019: Approved Treatment and Upcoming Therapeutic StrategiesПодробнее

Cure SMA Webinar on Spinraza(TM) Approval - U.S. OnlyПодробнее

Nusinersen Treatment for Older Patients with SMAПодробнее

U.S. FDA Approves Biogen’s SPINRAZA™ (nusinersen), The First Treatment for Spinal Muscular AtrophyПодробнее

Real-World Experience Treating SMA With NusinersenПодробнее

Cure SMA's Zolgensma FDA Approval WebinarПодробнее

Nusinersen: ASO(Anti-Sense- Oligonucleotide) Therapy toward Spinal Muscular Atrophy (SMA) #Code: 198Подробнее

MDA Enagage Webinar: The Treatment Landscape of SMAПодробнее